Dr. Lin has more than thirty years experience in drug discovery & development in biotech, leading discovery/preclinical development teams and clinical projects across cancer and inflammatory diseases. Passionate about developing new medicines in diseases with unmet medical needs.
Prior to joining AgnistaBio, he served as Chief Scientific Officer of Tianti Biotherapeutics and AltruBio Inc, subsequently. He founded AbGenomics Corp. and served as Chief Executive Officer from 2000 to 2006. To efficiently collaborate with top talents and key opinion leaders in both inflammation and cancer fields, he founded AbGenomics International Inc. (2006 – 2020) in San Francisco Bay Area. With the help of experts, Dr. Lin established Internal Control procedures and Corporate Governance including independent board directors in the company while company is still in private status. Within about twelve years, he raised about $120 M to support the company’s innovative new drug development. He is the key inventor of more than twenty worldwide patents. Under his leadership and well-established collaborative culture, the company discovered six promising new therapeutic candidates and has filed seven INDs and completed seven clinical trials successfully. The lead compound his team discovered has demonstrated significant clinical proof of efficacy in four different diseases.
Prior to joining AbGenomics, Dr. Lin was founding Professor and Director of Graduate Institute of Immunology, College of Medicine, National Taiwan University (1991 – 2000). He also served as an Associate Editor for Journal of Biomedical Science (1998 – 2002) and a member of the Editorial Board for Int. Immunopharmacology (2001-2007).
He received his “Diplom” Degree, Summa Cum Laude (major in Biotechnology: focus on drug discovery; minor in Biochemistry, Molecular Genetics, and “Phytopharmaka”), and Doctor Degree in Immunology, Magna Cum Laude, from the University of Tübingen in Germany. He has conducted his research works in three world renowned institutions: Max Planck Institute for Immunogenetics in Germany (with Dr. Jan Klein, 1984-1987), Basel Institute for Immunology in Switzerland (1987-1989), and Immunobiology Division at Howard Hughes Medical Institute at Yale University (with Dr. Charles Janeway, 1989-1991). In his 14-year academic research journey he has supervised 8 physician scientists from different departments of NTU hospital (Rheumatology, Dermatology, Inner Medicine, Gynecology, Oncology, and Urology) to conduct translational research and published about 50 refereed papers.
